o. Univ.-Prof. Dr. med. Dr. h. c. mult.

Josef Smolen

Josef Smolen

Full Member of the Division of Mathematics and Natural Sciences since 2005

  • Universitätsklinik für Innere Medizin III, Medizinische Universität Wien

Contact:

Research Areas:

  • Clinical Medicine
  • Rheumatology
  • Immunology
  • Medical diagnostics
  • Disability studies
  • Outcomes research

Selected Memberships:

  • Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften
  • Royal College of Physicians, London
  • American Association of Immunologists
  • American College of Rheumatology
  • Österreichische Gesellschaft für Allergologie und Immunologie
  • Österreichische Gesellschaft für Rheumatologie

Selected Prizes:

  • Dr. h. c. Leiden University, The Netherlands
  • Dr. h. c. Lund University, Sweden
  • Fellow of the Royal College of Physicians, London
  • Ehrenmitglied der Italienischen Gesellschaft für Rheumatologie
  • Dr. h.c. Semmelweis University, Budapest

Selected Publications:

  • Smolen, J. S.; Nash, P.; Durez, P. et al. (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet, Bd. 381 (9870), S. 918-929.
  • Smolen J. S., Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302.
  • Smolen J. S., Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019 Jun 8; 393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23.
  • Smolen, J. S.; Beaulieu, A.; Rubbert-Roth, A. et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet, Bd. 371 (9617), S. 987-997.
  • Smolen, J. S.; Kalden, J. R.; Scott, D. L. et al. (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet, Bd. 353 (9149), S. 259-266.